A plain-language guide · Questions to bring
Ask for answers you can explain back.

If the conversation feels full of unfamiliar words, choose the questions that matter most now. There is no need to ask them in a special order.
Begin with your own care goal
- What do you think is causing the concern I have described?
- Which options with stronger evidence can we discuss?
- What would you look at to judge whether care is helping?
If Selank is proposed, get specific
- What exact product are you discussing, and who makes it?
- Which law allows you to provide this exact product to me in my state?
- Which human study best matches my problem?
- What did that study compare, and what does it leave unanswered?
- What is unknown about harm or about combining it with what I take?
Why those questions matter here
There was no US Selank medicine with FDA approval to identify as of September 30, 2026.
The patient evidence is from small anxiety studies in Russia that lacked a placebo group, or dummy-treatment comparison.
The FDA also says important information about harm in people is missing.
A useful answer names the product, connects the evidence to your concern, and acknowledges the gaps. When an unfamiliar term comes up, request an explanation of how it relates to the decision under discussion.
End with practical details
- What is included in the visit charge?
- Who handles questions after the visit?
- What happens if a test, another opinion, or in-person care is needed?
- Can I have the next step and its cost in writing?
Open the sources for this page
Source checks behind these answers: September 30, 2026.
- FDA records for Selank
Use this FDA search to check whether a Selank medicine has US approval.
- Journal record of the anxiety comparison
The English summary compares Selank with another medicine; there was no dummy-treatment group.
- Journal record of the add-on comparison
The English summary describes Selank added to another calming medicine.
- FDA entry on missing information
The FDA still reports missing information about harm from Selank; taking back a request for pharmacy use did not resolve those concerns.